Oral Edaravone–Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis

Gary L. Pattee, Angela Genge, Philippe Couratier, Christian Lunetta, Gen Sobue, Masashi Aoki, Hiide Yoshino, Carlayne E. Jackson, James Wymer, Alejandro Salah, Sally Nelson

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations

Abstract

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and incurable neurodegenerative disease. While pharmacotherapy options remain limited, the Food and Drug Administration (FDA) approved intravenous (IV) and oral edaravone for the treatment of ALS in 2017 and 2022, respectively. With the addition of oral edaravone, patients with ALS may exclusively use oral medications. Areas covered: The authors performed a review of the published literature using the United States (US) National Library of Medicine’s PubMed.gov resource to describe the pharmacokinetics, pharmacodynamics, safety, and efficacy of oral edaravone, as well as pertinent completed and ongoing clinical trials, including the oral edaravone clinical trial development program. The clinical profile of oral edaravone is also discussed. Expert opinion: Edaravone has been shown to slow the rate of motor function deterioration experienced by patients with ALS. As the oral formulation has been approved, patients with ALS may use it alone or in combination with other approved therapeutics. Additional clinical trials and real-world evidence are ongoing to gain further understanding of the clinical profile of oral edaravone.

Original languageEnglish (US)
Pages (from-to)859-866
Number of pages8
JournalExpert Review of Neurotherapeutics
Volume23
Issue number10
DOIs
StatePublished - 2023

Keywords

  • Amyotrophic lateral sclerosis
  • clinical trials
  • edaravone
  • neuromuscular degeneration
  • oral formulation
  • safety

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • General Neuroscience

Fingerprint

Dive into the research topics of 'Oral Edaravone–Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis'. Together they form a unique fingerprint.

Cite this